Login to Your Account

'Axsome'-mum benefit? Phase III tests fixed-dose pairing in stubborn MDD

By Randy Osborne
Staff Writer

Thursday, March 17, 2016

Axsome Therapeutics Inc. is hoping the fixed-dose marriage of dextromethorphan with established depression player bupropion in oral AXS-05 will do the trick against treatment-resistant depression  in the newly launched phase III trial called STRIDE-1.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription